Spain's Sanifit Developing Unique Microcrystal Inhibitor For Calcification In Renal Disease
This article was originally published in Scrip
Spain's fledgling life sciences biotech company Laboratoris Sanifit SL is developing a drug for vascular calcification that has a unique mode of action; it acts to inhibit pathological crystallization processes rather than targeting a receptor, enzyme or protein.
You may also be interested in...
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.